MedPath

Prevention of Persistent Opioid Use in Mothers

Phase 4
Completed
Conditions
Opioid Use
Postpartum Disorder
Chronic Pain Syndrome
Interventions
Drug: Placebo
Registration Number
NCT03472521
Lead Sponsor
Stanford University
Brief Summary

Our previous work has identified the group of women at risk for prolonged pain, opioid use and poor functional recovery after childbirth. The optimal intervention to mitigate this risk is unknown. We propose to test an analgesic adjutant that is commonly used for post-operative pain compared to placebo to improve post-partum recovery.

Detailed Description

A small percent of the large population of women who give birth have difficulty with prolonged pain, opioid use and poor functional recovery. This may be the first opiate exposure and significant health challenge in a young woman's life.

In our previous work, we have identified 20% who are at highest risk for prolonged pain and delayed opioid cessation and functional recovery with usual care. Moderate to severe pain on postpartum day 1 is a significant predictor of being in the risk group. The optimal intervention to mitigate this risk is unknown.

We plan to test an intervention of low dose gabapentin or placebo to be escalated by a pain medicine doctor as needed. We hypothesize that additional care of women predicted to be higher need by virtue of their postoperative day one pain score (\> 6 x2) despite usual multimodal analgesic care will lead to reduced need for opioid, less pain and more rapid functional recovery.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
78
Inclusion Criteria
  • Delivery within 5 days, able to provide informed consent, English speaker
Exclusion Criteria
  • Opiate use disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlPlaceboMatched placebo capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
GabapentinGabapentinGabapentin 300 mg capsules will be prescribed at a starting dose of 1 capsule three times a day and titrated on the recommendation of a chronic pain specialist.
Primary Outcome Measures
NameTimeMethod
Time to Opioid Cessation as a Measure of Opioid UtilizationUp to 12 weeks
Secondary Outcome Measures
NameTimeMethod
Pain Report12 weeks

Number of weeks after delivery until resolution of pain as reported by participants. Pain score was averaged each week from daily reporting by participants using a numerical rating scale (range: 1-10, 1 = no pain; 10 = worst pain).

Functional Recovery12 weeks

Functional recovery was assessed as the number of weeks after delivery until participants reported they were able to return to pre-delivery function.

Trial Locations

Locations (1)

Lucille Packard Children's Hospital

🇺🇸

Palo Alto, California, United States

© Copyright 2025. All Rights Reserved by MedPath